Búsqueda de un ensayo clínico
Otra(s) opcion(es) de búsqueda
146 Resultado(s)
Ensayo clínico en reclutamiento
= 
; Ensayos clínico en curso
= 
; Ensayo clínico finalizado
= 
; Financiado por un miembro del IRDiRC = 
; Miembro de una ERN = 
Ensayo(s) clínico(s) nacional(es)
ALEMANIA
Baden-Württemberg
HEIDELBERG
CHARLY: Phase-II study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma
Zentrum für Innere Medizin (Krehl-Klinik)
Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie
ALEMANIA
Baden-Württemberg
MANNHEIM
Phase IIA Study on Therapy in Patients With Cutaneous T Cell Lymphoma - DE
Universitätsmedizin Mannheim
Klinik für Dermatologie, Venerologie und Allergologie
ALEMANIA
Nordrhein-Westfalen
MINDEN
TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma -DE-
Johannes Wesling Klinikum Minden
Universitätsklinik für Dermatologie, Venerologie, Allergologie und Phlebologie
BELGICA
NAMUR
YVOIR
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma - BE
Cliniques Universitaires UCL de Mont-Godinne
Department of Hematology
CANADA
Colombie-Britannique
VANCOUVER
ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - CA
British Columbia Cancer Agency
CANADA
Ontario
TORONTO
ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - CA
Sunnybrook Health Sciences Centre
Sunnybrook Research Institute
CANADA
Québec
MONTRÉAL
ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - CA
The Research Institute of the McGill University Health Centre
CHINA
CHINA
ADDRESS: NOT PROVIDED - CN
A Phase 2, Single-Arm, Open-Label, Multicenter Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in the Frontline Treatment of Chinese Patients With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Institution: Information not provided - CN
DINAMARCA
Jylland
AARHUS
ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - DK
Aarhus Universitetshospital - Tage-Hansens Gade
Institut for Klinisk Medicin - Hæmatologisk afdeling R, THG
ESPAÑA
Cataluña
L'HOSPITALET DE LLOBREGAT
CheckMate 436: Estudio fase I/II para evaluar la seguridad y la eficacia preliminar de nivolumab en combinación con brentuximab vedotin en sujetos con linfomas no Hodgkin con expresión de CD30 en recidiva y refractario - ES
ICO Hospitalet - Hospital Duran i Reynals
Servicio de Hematología Clínica
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
TELLOMAK: Tratamiento anti-KIR3DL2 para el linfoma de linfocitos T. Estudio en fase II, multicéntrico, abierto y de varias cohortes para evaluar la eficacia y la seguridad de IPH4102 solo o en combinación con quimioterapia en pacientes con linfoma de linfocitos T Avanzado -ES
Institution: Information not provided - ES
ESTADOS UNIDOS
Pennsylvania
PHILADELPHIA
A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma - US
Perelman Center for Advanced Medicine
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - US
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Institution: Information not provided - US
FRANCIA
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma - FR
CHU de Lyon HCL - GH Sud
Service d'hématologie clinique
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
An Open-label, Treatment-option Protocol of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, or CD30-positive Cutaneous T-cell Lymphoma - FR
Institution: Information not provided - FR
FRANCIA
ILE-DE-FRANCE
PARIS
Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) - FR
GHU AP-HP Nord. Université de Paris - Hôpital Saint-Louis
Service de dermatologie
FRANCIA
PAYS DE LA LOIRE
NANTES
ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - FR
CHU de Nantes - Hôtel Dieu
Service d'hématologie clinique
FRANCIA
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
A Phase II Study of L19IL2/L19TNF in Patients With Skin Cancers Amenable to Intralesional Treatment.
CHU de Marseille - Hôpital de la Timone
ISRAEL
ISRAEL
ADDRESS: NOT PROVIDED - IL
ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - IL
Institution: Information not provided - IL
ITALIA
EMILIA ROMAGNA
BOLOGNA
A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma
IRCCS Policlinico Sant'Orsola
Dipartimento di Ematologia e Scienze Oncologiche
ITALIA
LOMBARDIA
MILANO
ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - IT
ASST Grande Ospedale Metropolitano Niguarda
S.C di Ematologia
POLONIA
Bydgoszcz
BYDGOSZCZ
Comparison of methotrexate versus interferon-alfa 2b on efficacy, safety and quality of life in patients with primary cutaneous T-cell lymphomas after failure of topical or phototherapy treatment.
Centrum Onkologii im. prof. F. Lukaszczyka
POLONIA
Kraków
ADDRESS: NOT PROVIDED - PL
ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas - PL
Institution: Information not provided - PL
PORTUGAL
NORTE
PORTO
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas (Phase III)
Instituto Português de Oncologia do Porto Francisco Gentil, EPE
Serviço de Onco-Hematologia
PORTUGAL
SUL
LISBOA
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas (Phase III)
Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital de Santa Maria
Serviço de Hematologia e Transplantação de Medula
PORTUGAL
SUL
LISBOA
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas (Phase III)
Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE
Departamento de Hematologia
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
CHEMO-T: Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre randomised phase II study - UK
University of Cambridge
Department of Medicine
REINO UNIDO (EL)
Greater Manchester
MANCHESTER
NCRN2401 - An open-label, treatment-option protocol of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, or CD30-positive cutaneous T-cell lymphoma (Phase II) - UK
The Christie, NHS Foundation Trust
Department of Medical Oncology
REINO UNIDO (EL)
West Midlands
BIRMINGHAM
TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma-GB
University of Birmingham
University of Birmingham HQ
REPUBLICA CHECA (LA)
Capital City Prague
ADDRESS: NOT PROVIDED - CZ
ECHELON-2: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas - CZ
Institution: Information not provided - CZ
SUIZA
Suisse Alémanique
BERN
Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study
Inselspital Universitätsspital
Universitätsklinik für Medizinische Onkologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
RESMAIN: A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype, Who Have Completed the SOLAR Study (Phase 2) - AT
Institution: Information not provided - AT
ESPAÑA
Cataluña
BARCELONA
Inmunoterapia con linfocitos T diferenciados, adultos, autólogos, de sangre periférica, expandidos y transducidos (modificados genéticamente) mediante un vector lentiviral para que expresen un receptor quimérico con especificidad anti-CD30 asociado a secuencias coestimuladoras 4-1-BB y CD3z en pacientes con linfoma de Hodgkin clásico y linfoma no-hodgkin T con expresión CD30 -ES
Hospital de la Santa Creu i Sant Pau
Servicio de Hematología
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio RESMAIN: Estudio multicéntrico, doble ciego, aleatorizado, controlado con placebo, de fase II para evaluar Resminostat para el tratamiento de mantenimiento de pacientes con estadio avanzado (estadio IIB-IVB) de micosis fungoide (MF) o Síndrome de Sézary (SS) que hayan logrado el control de la enfermedad con la terapia sistémica -ES
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
MOGAT: Estudio de fase II, abierto y multicéntrico del anticuerpo monoclonal anti-CCR4 (mogamulizumab) más radioterapia total de la piel con haz de electrones (Total Skin Electron Beam, TSEB) en pacientes con linfoma cutáneo de linfocitos T en estadio IB-IIB -ES
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase 2 abierto para evaluar la seguridad de mogamulizumab administrado cada 4 semanas después de la inducción en participantes con linfoma cutáneo de linfocitos T (LCLT) recidivante o resistente -ES
Institution: Information not provided - ES
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides
Institution: Information not provided - US
ALEMANIA
Baden-Württemberg
HEIDELBERG
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Deutsches Krebsforschungszentrum
Klinische Kooperationseinheit Pädiatrische Onkologie
ALEMANIA
Bayern
REGENSBURG
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Regensburg
Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation
ALEMANIA
Bayern
WÜRZBURG
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universitätsklinikum Würzburg
ALEMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
PIVOT IO 020: Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies - DE
Institution: Information not provided - DE
ALEMANIA
Berlin
BERLIN
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Charité - Universitätsmedizin Berlin
ALEMANIA
Nordrhein-Westfalen
ESSEN
INFORM2 NivEnt: exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies
Universitätsklinikum Essen
Klinik für Kinderheilkunde III
ALEMANIA
Nordrhein-Westfalen
MÜNSTER
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE
Universitätsklinikum Münster
ALEMANIA
Sachsen
LEIPZIG
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase I/IIa study of intra-tumoral BT-001 (TG6030) administered alone and in combination with pembrolizumab in patients with cutaneous or, subcutaneous lesions or easily injectable lymph nodes of metastatic/advanced solid tumors - BE
Cliniques universitaires Saint-Luc - UCLouvain
Service d'oncologie médicale
BELGICA
WEST-VLAANDEREN
BRUGGE
A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination With JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - BE
AZ Sint-Jan Brugge
Hematologie
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio de fase 1, abierto, de búsqueda de dosis para evaluar la seguridad, tolerabilidad, farmacocinética y eficacia preliminar de CC-90010 en sujetos con tumores sólidos avanzados y linfomas no Hodgkin en recaída/refractario -ES
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
UNITY: Estudio aleatorizado de fase IIb para evaluar la eficacia y la seguridad de la combinación de ublituximab + TGR-1202 con o sin bendamustina y TGR-1202 en monoterapia en pacientes con linfoma no Hodgkin tratados previamente -ES
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Primera fase en un estudio de escalada de dosis en humanos de ZN-d5 como agente único en sujetos con linfoma no Hodgkin o leucemia mieloide aguda
Institution: Information not provided - ES
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio abierto en fase Ib de la seguridad, farmacocinética y farmacodinamia de JNJ-64264681 en combinación con JNJ-67856633 en pacientes con linfoma no-hodgkin y leucemia linfocítica crónica
Institution: Information not provided - ES
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
An Open-label, Phase 1b Study of ACP 196 Alone or in Combination With Rituximab in Subjects With Follicular Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Institution: Information not provided - US
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
Institution: Information not provided - FR
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -FR
Institution: Information not provided - FR
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) - BRUIN -FR
Institution: Information not provided - FR
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination With JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia -FR
Institution: Information not provided - FR
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020) -FR
Institution: Information not provided - FR
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.-FR
Institution: Information not provided - FR
FRANCIA
ILE-DE-FRANCE
VILLEJUIF
Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin's Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia
CLCC Institut Gustave Roussy
Département d'hématologie
FRANCIA
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid®) With Rituximab in Subjets With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma (Phase II) - FR
CLCC Institut Paoli Calmettes
Institut Paoli-Calmettes
ISRAEL
ISRAEL
ADDRESS: NOT PROVIDED - IL
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies -IL
Institution: Information not provided - IL
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR alfa-beta+ T cells in pediatric patients affected by hematological disorders - IT
Institution: Information not provided - IT
ITALIA
LAZIO
ROMA
CD19-CAR01: Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
ITALIA
LOMBARDIA
ROZZANO
A Phase II Prospective Study of High-dose Myeloablative Therapy, With Stem Cell Devices Support in Elderly Patients (>65 and <75 Years) With Relapsed Aggressive Non-Hodgkin Lymphoma or Resistant to First Line Therapy
IRCCS Istituto Clinico Humanitas
U.O. Oncologia Medica ed Ematologia
ITALIA
PIEMONTE
TORINO
Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette
S.C. di Ematologia
JAPON
JAPAN
ADDRESS : NOT PROVIDED - JP
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (BRUIN)
Institution: Information not provided - JP
PAISES BAJOS (LOS)
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma -GB
Addenbrooke's Hospital
Cambridge Cancer Trials Centre
REINO UNIDO (EL)
Greater London
LONDON
Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders-GB
GOSH NHS Foundatin Trust
Great Ormond Street Hospital
REINO UNIDO (EL)
Greater London
LONDON
UK Haplo v1.0: A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies
Guy's Hospital
Department of Haematology
REINO UNIDO (EL)
Greater London
LONDON
MoTD: A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide
UCL Cancer Institute, University College London
Department of Haematology
REINO UNIDO (EL)
Greater London
UXBRIDGE
REINO UNIDO (EL)
Greater Manchester
MANCHESTER
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies -GB
The Christie, NHS Foundation Trust
The Christie NHS Foundation Trust
SUIZA
Suisse Italienne
BELLINZONA
A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) - BRUIN - CH
Ospedale Regionale di Bellinzona e Valli
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
COVID-19: A Phase 3, open-label, parallel group, multicenter clinical study to evaluate the safety, reactogenicity, and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in participants 45 years or older with either a solid tumor or hematologic malignant disease who are receiving or scheduled to receive systemic anticancer therapy (independent of intent) - AT
Institution: Information not provided - AT
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-label, Phase I/II Study to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Anticancer Activity of Avelumab in Pediatric Subjects From Birth to Less Than 18 Years of Age With Refractory or Relapsed Solid Tumors and Lymphoma - BE
Cliniques universitaires Saint-Luc - UCLouvain
Cliniques Universitaires Saint-Luc
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
Open-label, Phase I/II Study to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Anticancer Activity of Avelumab in Pediatric Subjects From Birth to Less Than 18 Years of Age With Refractory or Relapsed Solid Tumors and Lymphoma-CA
Institution: Information not provided - CA
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Institution: Information not provided - US
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma - IT
Institution: Information not provided - IT
ITALIA
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
REINO UNIDO (EL)
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase I/II, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours and Lymphoma.
Institution: Information not provided - GB
Ensayo(s) clínico(s) multinacional(es)
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A phase III study of lenalidomide maintenance after debulking with gemcitabine or liposomal doxorubicin +/- radiotherapy in patients with advanced cutaneous T-cell lymphoma not previously treated with intravenous chemotherapy (Coordination)
Institution: Information not provided - BE
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A Phase 2, Single-arm, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma (Coordination)
Institution: Information not provided - BE
ESTADOS UNIDOS
California
LOS ANGELES
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Children's Hospital Los Angeles
Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (Coordination)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy (Coordination)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
An open-label, phase 2/3, treatment-option protocol of brentuximab vedotin in patients with progression of Hodgkin lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
ECHELON-2: A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma (Phase III)
Institution: Information not provided - US
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma
Institution: Information not provided - FR
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
Institution: Information not provided - FR
FRANCIA
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
ALEMANIA
Bayern
MARTINSRIED/PLANEGG
ALEMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
A-CHOP-14 (elderly) : A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma
Institution: Information not provided - DE
ALEMANIA
Hessen
DARMSTADT
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PARCT: Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment
EORTC
European Organisation for the Research and Treatment of Cancer
ESTADOS UNIDOS
Colorado
BOULDER
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma - Coordination
Institution: Information not provided - FR
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
A Phase I/IIa Study of Intra-tumoral BT-001 (TG6030) Administered Alone and in Combination With Pembrolizumab in Patients With Cutaneous or, Subcutaneous Lesions or Easily Injectable Lymph Nodes of Metastatic/Advanced Solid Tumors.
Institution: Information not provided - BE
ESTADOS UNIDOS
New Jersey
SUMMIT
ESTADOS UNIDOS
Texas
HOUSTON
Follow-up of Phase 1/2 Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR α β+T Cells in Pediatric Patients Affected by Hematological Disorders
Bellicum Pharmaceuticals, Inc.
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1a/1b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma (Coordination)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination With JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) - BRUIN
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Phase 1 First in Human Dose-Escalation Study of ZN-d5 as a Single Agent in Subjects With Non-Hodgkin Lymphoma or Acute Myeloid Leukemia
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1B, Multicenter, Open-label Study to Determine the Safety, Pharmacokinetics and Preliminary Efficacy of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies
Institution: Information not provided - US
NORUEGA
Østlandet
ADDRESS: NOT PROVIDED - NO
A Double-blind, Randomized, Placebo-controlled Cross Over Study of Inhaled Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis
Institution: Information not provided - NO
REINO UNIDO (EL)
Greater London
ADDRESS: NOT PROVIDED - GB
An Open-label, Multi-Center, Non-Randomised Phase I Dose-Escalation Study to Investigate the Safety and Tolerability of ONO-4059 (ONO/GS-4059) Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)
Institution: Information not provided - GB
SUIZA
Suisse Alémanique
BASEL
An Open-label, Multi-center, Randomized Study to Evaluate the Efficacy on Tumor Response of GA101 (RO5072759) Monotherapy Versus Rituximab Monotherapy in Patients With Relapsed CD20+ Indolent Non-Hodgkin's Lymphoma (Phase II) (coordination)
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
Open-label, Phase I/II Study to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Anticancer Activity of Avelumab in Pediatric Subjects From Birth to Less Than 18 Years of Age With Refractory or Relapsed Solid Tumors and Lymphoma
Institution: Information not provided - US
ESPAÑA
Madrid
COLMENAR VIEJO